One of the most recent and perhaps most promising developments in psoriasis research is the role of the Th17 CD4 + T cell and one of its cytokines, IL-17, in disease development, progression and ...

Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasisTop-line data from the 12-week double-blind ...

Aclaris Therapeutics (ACRS) announced the availability of a new publication describing properties of Aclaris Therapeutics’ ATI-2138, a novel ...

Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., ...

Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasis Top-line data from the 12-week double-blind trial expected by year-end 2025 Phase 1b trial designe ...

Objectives We aimed to examine alteration of the Th1/Th2/Th17 cytokine profile and humoral indicators caused by occupational chromate exposure. Methods A cross-sectional study was conducted in two ...

These cytokines in turn activate the IL-23 and/or IL-22 pathway to induce Th17 and/or Th22 cell differentiation, resulting in the production of numerous psoriatic cytokines, such as TNF-α, IFN-γ, ...

Th17-related cytokines have been shown to enhance osteoclastogenesis, mainly via synovial fibroblasts. Thus, mesenchymal cells are a determinant of the development of RA that links the systemic immune ...

Guselkumab targets the p19 alpha subunit of IL-23. While IL-23 promotes normal inflammatory and immune responses, the p19 and ...